Febrile Neutropenia (FN) is a potentially life-threatening and dose-limiting complication of myelosuppressive chemotherapy (CT) that often requires hospital admission (HA). Patients (pts) with FN must initiate antibiotic (atb) therapy promptly and delay in diagnosis and subsequent treatment are associated with higher mobility and mortality.
Retrospective single institution review of all FN episodes that occurred in the years 2012 to 2016 in pts with solid tumors with an absolute neutrophil count (ANC) 38 °C and ANC
Among 1.947 eligible pts, 152 had a NF (8%) with a total of 173 NF episodes. Median age was 67yo; 90 were males (59%). Median initial ANC was 310/µl, range 20-990 (
FN is a serious and common complication of CT treatment which must be diagnosed and treated rapidly. Delays in the evaluation of febrile cancer pts on systemic treatment may compromise the outcome of these pts.
Clinical trial identification
Legal entity responsible for the study
João Moreira Pinto
All authors have declared no conflicts of interest.